MOLECULAR MARKERS FOR PROSTATE CANCER: OPTIMIZATION OF NON-INVASIVE DIAGNOSTICS

DOI: 
10.29296/24999490-2018-03-03

E.I. Surkova(1), M.G. Gordiev(2), D.A. Viktorov(3), A.G. Nikitin(4), A.N. Toropovski(3)
1-«TestGene», 44th Inzhenerny proezd, 9, Ulyanovsk, 432072, Russian Federation;
2-Tatarstan Regional Clinical Cancer Center, Sibirskiy tract, 29, Kazan, 420029, Russian Federation,;
3-«GeNext», 44th Inzhenerny proezd, 9, Ulyanovsk, 432072, Russian Federation;
4-Federal Scientific-clinical Center of specialized types of medical care and medical technologies,
Orekhovy boulevard, 28, Moscow, 115682, Russian Federation
E-mail: katerina-u48@mail.ru

The prostate cancer (PCa) incidence rate rises steadily among males all over the world. Over the past twenty years, the prostate-specific antigen (PSA) definition level in the patient's blood has been used for the PCa non-invasive diagnostics. However, due to the low specificity this method leads to the appointment of a large unnecessary biopsies number, overdiagnostics and excessive PCa treatment all over the world. Better understanding of PCa signaling pathways leads to markers identification that could be used to improve the PCa diagnostics. Now searching for the new molecular markers for early PCa diagnostics which should have good significance for disease prognosis and the expected response to therapy, is particularly acute. The presented review is devoted to the modern research analysis of molecular noninvasive PCa diagnostics and contains a description of both already introduced into clinical practice (PCA3 and TMPRSS2-ERG are used to determine the need for repeat biopsy) and new promising markers for this purpose.
Keywords: 
prostate cancer, noninvasive diagnostics, molecular genetic markers, PCA3, TMPRSS2-ERG